Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection
Authors
Keywords
-
Journal
INFLAMMATION RESEARCH
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-20
DOI
10.1007/s00011-021-01445-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- COVID-19: combining antiviral and anti-inflammatory treatments
- (2020) Justin Stebbing et al. LANCET INFECTIOUS DISEASES
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
- (2020) Timothy P. Sheahan et al. Nature Communications
- Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials
- (2020) Frits van Rhee et al. Lancet Haematology
- Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
- (2020) Ali Şahin et al. Advances in Rheumatology
- COVID‐19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine
- (2020) Francesco Fontana et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
- (2020) Achille Aouba et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD
- (2020) Carina Mihai et al. ANNALS OF THE RHEUMATIC DISEASES
- Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
- (2020) Shengyu Zhang et al. CLINICAL DRUG INVESTIGATION
- Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
- (2020) Mehmet Soy et al. CLINICAL RHEUMATOLOGY
- Perspective: improving vitamin D status in the management of COVID-19
- (2020) Maryam Ebadi et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
- (2020) Farhad Seif et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
- (2020) Chi Zhang et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Use of anakinra in severe COVID-19: a case report
- (2020) Giovanni Filocamo et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
- (2020) Samir Jawhara INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Neurological manifestations and complications of COVID-19: A literature review
- (2020) Imran Ahmad et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Tocilizumab treatment in COVID-19: A single center experience
- (2020) Pan Luo et al. JOURNAL OF MEDICAL VIROLOGY
- COVID‐19 pneumonia treated with Sarilumab: a clinical series of eight patients
- (2020) Maurizio Benucci et al. JOURNAL OF MEDICAL VIROLOGY
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Guillain–Barré Syndrome Associated with SARS-CoV-2
- (2020) Gianpaolo Toscano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Individual variation of the SARS‐CoV‐2 receptor ACE2 gene expression and regulation
- (2020) Jiawei Chen et al. AGING CELL
- Type 1 interferons as a potential treatment against COVID-19
- (2020) Erwan Sallard et al. ANTIVIRAL RESEARCH
- COVID-19: Immunology and treatment options
- (2020) Susanna Felsenstein et al. CLINICAL IMMUNOLOGY
- The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”
- (2020) Gholam Hossein Meftahi et al. INFLAMMATION RESEARCH
- Neurobiology of COVID-19
- (2020) Majid Fotuhi et al. JOURNAL OF ALZHEIMERS DISEASE
- COVID-19 revisiting inflammatory pathways of arthritis
- (2020) Georg Schett et al. Nature Reviews Rheumatology
- Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
- (2020) Wei Luo et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
- (2020) Tomás Palanques-Pastor et al. European Journal of Hospital Pharmacy-Science and Practice
- Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
- (2020) Lun Wang et al. Frontiers in Cardiovascular Medicine
- Cytokine storm induced by SARS-CoV-2
- (2020) Peipei Song et al. CLINICA CHIMICA ACTA
- Convalescent plasma treatment for COVID‐19: Tempering expectations with the influenza experience
- (2020) Kanta Subbarao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Neurological consequences of COVID-19: what have we learned and where do we go from here?
- (2020) Abbas Jarrahi et al. Journal of Neuroinflammation
- Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
- (2020) Sean T. H. Liu et al. NATURE MEDICINE
- New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
- (2019) Paweł Kawalec et al. Therapeutics and Clinical Risk Management
- Pharmacokinetics of Anakinra in Subjects of Heavier Versus Lighter Body Weights
- (2019) Bing‐Bing Yang et al. CTS-Clinical and Translational Science
- IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
- (2019) Rudragouda Channappanavar et al. JOURNAL OF CLINICAL INVESTIGATION
- HESA-A Attenuates Hepatic Steatosis in NAFLD Rat Model Through the Suppression of SREBP-1c and NF-kβ
- (2019) M. Efati et al. International Journal of Peptide Research and Therapeutics
- The Pyrin Inflammasome in Health and Disease
- (2019) Oskar Schnappauf et al. Frontiers in Immunology
- Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock
- (2019) Marketa Bloomfield et al. Frontiers in Immunology
- Interferon α subtypes in HIV infection
- (2018) Kathrin Sutter et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Anakinra for the treatment of rheumatoid arthritis: a safety evaluation
- (2018) Julio Ramírez et al. Expert Opinion On Drug Safety
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Sertoli Cells Avert Neuroinflammation-Induced Cell Death and Improve Motor Function and Striatal Atrophy in Rat Model of Huntington Disease
- (2018) Houssein Ahmadi et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis
- (2018) Özkan Varan et al. Modern Rheumatology
- Interferon Independent Non-Canonical STAT Activation and Virus Induced Inflammation
- (2018) Yuchen Nan et al. Viruses-Basel
- Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study
- (2018) Maxime Samson et al. European Journal of Internal Medicine
- Coronavirus TGEV Evades the Type I Interferon Response through IRE1α-Mediated Manipulation of the miR-30a-5p/SOCS1/3 Axis
- (2018) Yanlong Ma et al. JOURNAL OF VIROLOGY
- The Dual Nature of Type I and Type II Interferons
- (2018) Amanda J. Lee et al. Frontiers in Immunology
- The molecular basis for differential type I interferon signaling
- (2017) Gideon Schreiber JOURNAL OF BIOLOGICAL CHEMISTRY
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
- (2017) Rudragouda Channappanavar et al. Seminars in Immunopathology
- Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
- (2017) Steffen Riethmueller et al. PLOS BIOLOGY
- The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis
- (2017) Claus Madsen Brain and Behavior
- STATs in NK-Cells: The Good, the Bad, and the Ugly
- (2017) Dagmar Gotthardt et al. Frontiers in Immunology
- Biotherapies in large vessel vasculitis
- (2016) Y. Ferfar et al. AUTOIMMUNITY REVIEWS
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome
- (2016) Bita Shakoory et al. CRITICAL CARE MEDICINE
- Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17
- (2016) Steffen Riethmueller et al. Scientific Reports
- Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease
- (2015) C. Casper et al. CLINICAL CANCER RESEARCH
- FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
- (2015) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- Interleukin-6: Biology, signaling and strategies of blockade
- (2015) Fred Schaper et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Interleukin-6 and its receptors: A highly regulated and dynamic system
- (2014) Janina Wolf et al. CYTOKINE
- Interferons: Success in anti-viral immunotherapy
- (2014) Fan-ching Lin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Interferons and Their Receptors in Birds: A Comparison of Gene Structure, Phylogenetic Analysis, and Cross Modulation
- (2014) Hao Zhou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
- (2014) John Mair-Jenkins et al. JOURNAL OF INFECTIOUS DISEASES
- Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
- (2014) Ali S Omrani et al. LANCET INFECTIOUS DISEASES
- Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology
- (2013) Sarah N. Lauder et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
- (2013) Jasper F.W. Chan et al. JOURNAL OF INFECTION
- Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities
- (2013) Jürgen Scheller et al. SEMINARS IN IMMUNOLOGY
- The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study
- (2013) Geoff Bellingan et al. Lancet Respiratory Medicine
- Cutting Edge: Inhibition of IL-6 Trans-Signaling Protects from Malaria-Induced Lethality in Mice
- (2012) C. M. Wunderlich et al. JOURNAL OF IMMUNOLOGY
- IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling
- (2012) J. Hoge et al. JOURNAL OF IMMUNOLOGY
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
- (2012) Charles A. Dinarello et al. NATURE REVIEWS DRUG DISCOVERY
- Interleukin-6 and cytochrome-P450, reason for concern?
- (2012) Sooha Kim et al. RHEUMATOLOGY INTERNATIONAL
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
- (2012) L. Sun et al. SCIENCE
- Therapeutic Targeting of the Interleukin-6 Receptor
- (2011) Toshio Tanaka et al. Annual Review of Pharmacology and Toxicology
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection
- (2011) Navkiran Gill et al. CELLULAR IMMUNOLOGY
- Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*
- (2011) Tanja Barkhausen et al. CRITICAL CARE MEDICINE
- Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1
- (2011) Y. Berda-Haddad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies
- (2008) Hal M. Hoffman et al. ARTHRITIS AND RHEUMATISM
- Human immunopathogenesis of severe acute respiratory syndrome (SARS)
- (2007) Mark J. Cameron et al. VIRUS RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started